Search
Delgocitinib
go.drugbank.com/drugs/DB16133ApprovedInvestigationalDelgocitinib is a pan-Janus kinase (JAK) inhibitor. After the first global approval in Japan, delgocitinib was also approved by the European Commission on September 23, 2024. It works to reduce the inflammatory response in inflammatory s...
Categories: P-glycoprotein substratesEnsifentrine
go.drugbank.com/drugs/DB16157ApprovedInvestigationalEnsifentrine is a first-in-class, selective dual inhibitor of the phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4) enzymes. On June 26, 2024, the FDA announced the approval of an inhaled product of ensifentrine for the treatment...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 SubstratesLazertinib
go.drugbank.com/drugs/DB16216ApprovedInvestigationalLazertinib is an oral, third-generation, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). Lazertinib was first approved in South Korea on January 18, 2021, for the treatment of EGFR T790M mutation-positive non-sma...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsLonapegsomatropin
go.drugbank.com/drugs/DB16220ApprovedInvestigationalLonapegsomatropin, also known as TransCon hGH or ACP 001, is a methoxypegylated prodrug of human growth hormone (somatropin) indicated for the treatment of children 1 year and older, weighing at least 11.5 kg, with growth failure due to ...
Categories: P-glycoprotein substrates, Cytochrome P-450 CYP1A2 InducersLoncastuximab tesirine
go.drugbank.com/drugs/DB16222ApprovedInvestigationalRelapsed and refractory B-cell acute lymphoblastic leukemia (B-ALL) are a therapeutic challenge for patients who have undergone prior systemic therapies with limited success. Prognosis is poor and more effective therapies are needed to t...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesMiricorilant
go.drugbank.com/drugs/DB16234InvestigationalMiricorilant is under investigation in clinical trial NCT03818256 (Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adult Patients With Schizophrenia and Recent Weight Gain While Taking An...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 SubstratesOlutasidenib
go.drugbank.com/drugs/DB16267ApprovedInvestigationalOlutasidenib (FT-2102) is a selective and potent isocitrate dehydrogenase-1 (IDH1) inhibitor approved by the FDA in December 2022. It is indicated for the treatment of relapsed or refractory acute myeloid leukemia (AML) in patients with ...
Categories: Cytochrome P-450 CYP1A2 Inducers, P-glycoprotein inhibitorsTL-895
go.drugbank.com/drugs/DB16471InvestigationalTL-895 is a potent, orally active, ATP-competitive, and highly selective irreversible BTK inhibitor with an IC50 and a Ki of 1.5 nM and 11.9 nM, respectively. TL-895 is under investigation in several clinical trials for its safety and ef...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesBirch bark extract
go.drugbank.com/drugs/DB16536ApprovedInvestigational[A249945] Birch bark extract is obtained from the white part of the birch tree bark, and the main species of trees used for production are _Betula pendula_ Roth (silver birch) and _Betula pubescens_ Ehrh
Categories: Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 Enzyme Inhibitors